中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 40 Issue 4
Apr.  2024
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(4): 649-653

Current status of hepatitis C virus infection and progress in its elimination in China

DOI: 10.12449/JCH240401

  • Peking University People’s Hospital，Peking University Hepatology Institute，Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases，Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis，Beijing 100044，China

More Information
  • Corresponding author: RAO Huiying， rao.huiying@163.com （ORCID： 0000-0003-2431-3872）; CHEN Hongsong， chenhongsong@pkuph.edu.cn （ORCID： 0000-0001-6858-8398）
  • Received Date: 2024-03-08
  • Accepted Date: 2024-03-22
  • Published Date: 2024-04-25
    Abstract
  • Hepatitis C virus （HCV） can develop into liver cirrhosis or hepatocellular carcinoma， imposing a heavy burden on the patient’s family and the society. Hepatitis C is one of the major public threats for humans， and eliminating hepatitis C is a common goal of all humans. Direct-acting antiviral agents （DAAs） are currently a relatively safe treatment regimen for hepatitis C that can reach a relatively high cure rate and can target different HCV genotypes， making it possible to eliminate HCV infection. China actively promotes the clinical application of DAAs， accelerates drug approval， improves the accessibility of DAAs， and strengthens population intervention. National Medical Insurance Administration has gradually included DAAs in the national medical insurance directory， providing strong support for eliminating HCV infection. In response to the WHO’s goal of eliminating viral hepatitis as a public health hazard by 2030， China has successively released national strategic plans and action plans in recent years， making significant achievements in HCV infection elimination， forming a joint prevention and control system across multiple sectors of the society， and ultimately achieving the goal of eliminating HCV infection. With a focus on the current status of HCV infection in China and prominent prevention and control strategies， this article analyzes and summarizes the practical process of the prevention， control， and micro-elimination of HCV infection， in order to provide a policy reference for carrying out HCV elimination in China and help to achieve the goal of comprehensive elimination of HCV infection.

     

    • FullText(HTML)
    • References(32)
  • [1]
    CUI FQ, BLACH S, MANZENGO MINGIEDI C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C[J]. Lancet Gastroenterol Hepatol, 2023, 8( 4): 332- 342. DOI: 10.1016/S2468-1253(22)00386-7.
    [2]
    World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016- 2021. Towards Ending Viral Hepatitis,2016[M/OL].( 2016-05-17). https://www.who.int/publications/i/item/WHO-HIV-2016.06. https://www.who.int/publications/i/item/WHO-HIV-2016.06
    [3]
    World Health Organization. Combating Hepatitis B and C to Reach Elimination by 2030[M/OL].( 2016-05-27). https://www.who.int/publications/i/item/combating-hepatitis-b-and-c-to-reach-elimination-by-2030. https://www.who.int/publications/i/item/combating-hepatitis-b-and-c-to-reach-elimination-by-2030
    [4]
    LE LV, BLACH S, REWARI B, et al. Progress towards achieving viral hepatitis B and C elimination in the Asia and Pacific region: Results from modelling and global reporting[J]. Liver Int, 2022, 42( 9): 1930- 1934. DOI: 10.1111/liv.15131.
    [5]
    MARTINELLO M, SOLOMON SS, TERRAULT NA, et al. Hepatitis C[J]. Lancet, 2023, 402( 10407): 1085- 1096. DOI: 10.1016/s0140-6736(23)01320-x.
    [6]
    SCHINAZI RF, ASSELAH T. From HCV to HBV cure[J]. Liver Int, 2017, 37( Suppl 1): 73- 80. DOI: 10.1111/liv.13324.
    [7]
    BUTI M, LURIE Y, ZAKHAROVA NG, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response[J]. Hepatology, 2010, 52( 4): 1201- 1207. DOI: 10.1002/hep.23816.
    [8]
    COLLABORATORS POH. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: A modelling study[J]. Lancet Gastroenterol Hepatol, 2022, 7( 5): 396- 415. DOI: 10.1016/S2468-1253(21)00472-6.
    [9]
    RAO HY, WEI L, LOPEZ-TALAVERA JC, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection[J]. J Gastroenterol Hepatol, 2014, 29( 3): 545- 553. DOI: 10.1111/jgh.12398.
    [10]
    GOWER E, ESTES C, BLACH S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection[J]. J Hepatol, 2014, 61( 1 Suppl): S45- S57. DOI: 10.1016/j.jhep.2014.07.027.
    [11]
    WANG H, QIU Q, YUAN QL, et al. Epidemiological characteristics of incident cases and risk factors of hepatitis C infection in Beijing City from 2004 to 2021[J]. Chin J Prev Med, 2023, 57( 9): 1391- 1395. DOI: 10.3760/cma.j.cn112150-20221024-01026.

    王怀, 邱倩, 袁千里, 等. 2004—2021年北京市丙型肝炎流行特征及感染相关因素分析[J]. 中华预防医学杂志, 2023, 57( 9): 1391- 1395. DOI: 10.3760/cma.j.cn112150-20221024-01026.
    [12]
    DING X, REN DF, GAO QR, et al. Epidemiological characteristics of hepatitis C in Tongren from 2006 to 2020[J]. Mod Prev Med, 2022, 49( 6): 1003- 1005, 1015.

    丁旭, 任达飞, 高前荣, 等. 2006—2020年贵州省铜仁市丙型病毒性肝炎流行特征分析[J]. 现代预防医学, 2022, 49( 6): 1003- 1005, 1015.
    [13]
    LI N, FAN JX, QIU BH, et al. Epidemiological characteristics of hepatitis C in Jilin Province, 2012-2021[J]. Pract Prev Med, 2023, 30( 4): 474- 476. DOI: 10.3969/j.issn.1006-3110.2023.04.020.

    李娜, 范吉祥, 邱柏红, 等. 2012—2021年吉林省丙型肝炎流行病学特征分析[J]. 实用预防医学, 2023, 30( 4): 474- 476. DOI: 10.3969/j.issn.1006-3110.2023.04.020.
    [14]
    QIN LJ, LIU Y, GUO SM, et al. Prevalence characteristics and trend forecast of hepatitis C in Erqi district of Zhengzhou from 2013 to 2022[J]. J Henan Med Coll, 2023, 35( 5): 534- 538. DOI: 10.3969/j.issn.1008-9276.2023.05.015.

    秦利娟, 刘玉, 郭素梅, 等. 2013—2022年郑州市二七区丙型肝炎流行特征及趋势预测[J]. 河南医学高等专科学校学报, 2023, 35( 5): 534- 538. DOI: 10.3969/j.issn.1008-9276.2023.05.015.
    [15]
    XIAO L, TANG Y, WANG FS, et al. Epidemic status of viral hepatitis C in a district of Beijing, 2010—2022[J]. Cap J Public Health, 2023, 17( 5): 312- 315. DOI: 10.16760/j.cnki.sdggws.2023.05.008.

    肖雷, 唐莹, 王凤双, 等. 2010—2022年北京市某区丙型病毒性肝炎流行现状分析[J]. 首都公共卫生, 2023, 17( 5): 312- 315. DOI: 10.16760/j.cnki.sdggws.2023.05.008.
    [16]
    LIN CN, FENG Y, FENG XW. Current status of hepatitis C treatment and analysis of medical insurance compensation mechanism[J]. China Health Ind, 2022, 19( 5): 163- 167. DOI: 10.16659/j.cnki.1672-5654.2022.05.163.

    蔺朝妮, 冯玉, 冯晓伟. 丙型肝炎治疗现状与医保补偿机制分析[J]. 中国卫生产业, 2022, 19( 5): 163- 167. DOI: 10.16659/j.cnki.1672-5654.2022.05.163.
    [17]
    DU GP, LI XS, MUSA TH, et al. The nationwide distribution and trends of hepatitis C virus genotypes in Mainland China[J]. J Med Virol, 2019, 91( 3): 401- 410. DOI: 10.1002/jmv.25311.
    [18]
    YANG J, LIU HX, SU YY, et al. Distribution and changes in hepatitis C virus genotype in China from 2010 to 2020[J]. World J Clin Cases, 2022, 10( 14): 4480- 4493. DOI: 10.12998/wjcc.v10.i14.4480.
    [19]
    FENG XF, DING GW, YU HL, et al. Current status of hepatitis C diagnosis and treatment in Chinese medical institutions[J]. Chin J AIDS STD, 2020, 26( 3): 247- 249. DOI: 10.13419/j.cnki.aids.2020.03.06.

    冯小飞, 丁国伟, 俞海亮, 等. 医疗机构丙型肝炎诊断治疗现况研究[J]. 中国艾滋病性病, 2020, 26( 3): 247- 249. DOI: 10.13419/j.cnki.aids.2020.03.06.
    [20]
    LIU LL, XU HQ, HU Y, et al. Hepatitis C screening in hospitals: Find the missing patients[J]. Virol J, 2019, 16( 1): 47. DOI: 10.1186/s12985-019-1157-1.
    [21]
    HE N, HAO S, FENG G, et al. Analysis of the factors influencing the elimination strategies with the current status of diagnosis and treatment of hepatitis C in hospital[J]. Chin J Hepatol, 2021, 29( 11): 1053- 1058. DOI: 10.3760/cma.j.cn501113-20210119-00034.

    贺娜, 郝帅, 冯巩, 等. 医院内丙型肝炎诊治现状对院内消除策略的影响因素分析[J]. 中华肝脏病杂志, 2021, 29( 11): 1053- 1058. DOI: 10.3760/cma.j.cn501113-20210119-00034.
    [22]
    National Health Commission of the People’s Republic of China. Action Plan for Eliminating Public Health Hazards of Hepatitis C( 2021-2030)[EB/OL]. http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=c462ec94e6d14d8291c5309406603153. http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=c462ec94e6d14d8291c5309406603153

    中华人民共和国国家卫生健康委员会. 消除丙型肝炎公共卫生危害行动工作方案( 2021- 2030 年)[EB/OL]. http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=c462ec94e6d14d8291c5309406603153. http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXxgk.htm?id=c462ec94e6d14d8291c5309406603153
    [23]
    China Liver Health; Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Laboratory Medicine, Chinese Medical Association; Hospital Infection Management Committee of Chinese Hospital Association. In-hospital process for viral hepatitis C screening and management in China(Draft)[J]. J Clin Hepatol, 2021, 37( 7): 1534- 1539. DOI: 10.3969/j.issn.1001-5256.2021.07.011.

    中联肝健康促进中心, 中华医学会肝病学分会, 中华医学会检验医学分会, 等. 中国丙型病毒性肝炎院内筛查管理流程(试行)[J]. 临床肝胆病杂志, 2021, 37( 7): 1534- 1539. DOI: 10.3969/j.issn.1001-5256.2021.07.011.
    [24]
    Chinese Society of Health Management, Chinese Society of Hepatology, Chinese Society of Laboratory Medicine. Expert consensus on viral hepatitis health management(2021)[J]. Chin J Health Manag, 2021, 15( 4): 323- 331. DOI: 10.3760/cma.j.cn115624-20210531-00305.

    中华医学会健康管理学分会, 中华医学会肝病学分会, 中华医学会检验医学分会. 病毒性肝炎健康管理专家共识(2021年)[J]. 中华健康管理学杂志, 2021, 15( 4): 323- 331. DOI: 10.3760/cma.j.cn115624-20210531-00305.
    [25]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline for the prevention and treatment of hepatitis C(2022 version)[J]. Chin J Hepatol, 2022, 30( 12): 1332- 1348. DOI: 10.3760/cma.j.cn501113-20221220-00605.

    中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版)[J]. 中华肝脏病杂志, 2022, 30( 12): 1332- 1348. DOI: 10.3760/cma.j.cn501113-20221220-00605.
    [26]
    WU T, LIN F, WANG J, et al. Hepatitis C elimination among drug users in China:challenges,strategies and experiences[J]. Chin J Hepatol, 2022, 30( 9): 1002- 1006. DOI: 10.3760/cma.j.cn501113-20210311-00116.

    吴涛, 林锋, 王姣, 等. 中国吸毒人群中的丙型肝炎消除: 挑战、策略和经验[J]. 中华肝脏病杂志, 2022, 30( 9): 1002- 1006. DOI: 10.3760/cma.j.cn501113-20210311-00116.
    [27]
    CHENG HH, CAI DC. Enlightenment of practical experience of eliminating hepatitis C at home and abroad to update the prevention and treatment strategy of hepatitis C in China[J]. Chin J Infect Dis, 2023, 41( 3): 230- 233. DOI: 10.3760/cma.j.cn311365-20220428-00152.

    程欢欢, 蔡大川. 国内外消除丙型肝炎的实践经验对更新我国丙型肝炎防治策略的启发[J]. 中华传染病杂志, 2023, 41( 3): 230- 233. DOI: 10.3760/cma.j.cn311365-20220428-00152.
    [28]
    LUO XH, LIANG YD, PENG H, et al. Exploring the health education model for chronic hepatitis C micro-elimination in Guizhou Province from a global perspectives[J]. Chin J Hepatol, 2020, 28( 10): 816- 819. DOI: 10.3760/cma.j.cn501113-20200831-00484.

    罗新华, 梁跃东, 彭虹, 等. 从全球丙型肝炎微消除模式到贵州省慢性丙型肝炎健康教育模式的探索[J]. 中华肝脏病杂志, 2020, 28( 10): 816- 819. DOI: 10.3760/cma.j.cn501113-20200831-00484.
    [29]
    RAO HY, LI MY, WEI L. Elimination of hepatitis C,ourprogress,challenges and hopes[J]. Chin J Hepatol, 2020, 28( 10): 809- 811. DOI: 10.3760/cma.j.cn501113-20200929-00538.

    饶慧瑛, 李明阳, 魏来. 消除丙型肝炎, 我们的进展、挑战和希望[J]. 中华肝脏病杂志, 2020, 28( 10): 809- 811. DOI: 10.3760/cma.j.cn501113-20200929-00538.
    [30]
    YIM HJ. Elimination of hepatitis C: What would be the practical approach?[J]. Clin Mol Hepatol, 2021, 27( 1): 97- 99. DOI: 10.3350/cmh.2020.0304.
    [31]
    BAO YP, LARNEY S, PEACOCK A, et al. Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis[J]. Int J Drug Policy, 2019, 70: 87- 93. DOI: 10.1016/j.drugpo.2019.05.005.
    [32]
    LI J, PANG L, LI DM, et al. Hepatitis C case report and sentinel surveillance in China from 2015 to 2021[J]. Chin J AIDS STD, 2023, 29( 6): 634- 638. DOI: 10.13419/j.cnki.aids.2023.06.04.

    李健, 庞琳, 李东民, 等. 2015—2021年我国丙型肝炎病例报告与哨点监测分析[J]. 中国艾滋病性病, 2023, 29( 6): 634- 638. DOI: 10.13419/j.cnki.aids.2023.06.04.
    • Relative Articles

  • Relative Articles

    [1]Danqing XU, Huan MU, Yingyuan ZHANG, Lixian CHANG, Yuanzhen WANG, Weikun LI, Zhijian DONG, Lihua ZHANG, Yijing CHENG, Li LIU. Influencing factors for recompensation in patients with decompensated hepatitis C cirrhosis[J]. Journal of Clinical Hepatology, 2025, 41(2): 269-276. doi: 10.12449/JCH250212
    [2]Jian LI, Fuzhen WANG, Zhongdan CHEN, Jinlei QI, Ailing WANG, Fanghui ZHAO, Yuanyuan KONG, Jing SUN, Jiaqi KANG, Zundong YIN, Zhongfu LIU, Jidong JIA, Yu WANG. Research advances in the disease burden of viral hepatitis in China[J]. Journal of Clinical Hepatology, 2025, 41(2): 221-227. doi: 10.12449/JCH250205
    [3]Yu WANG. Public health management strategies： A pathway to eliminating viral hepatitis threats[J]. Journal of Clinical Hepatology, 2025, 41(2): 201-204. doi: 10.12449/JCH250201
    [4]Jian LI, Zhongfu LIU. Advances， achievements， and challenges in action to eliminate hepatitis C as a public health threat in China[J]. Journal of Clinical Hepatology, 2025, 41(2): 216-220. doi: 10.12449/JCH250204
    [5]Xin LIU, Jia LI, Fengmin LU. The way is simple： A brief natural history of chronic hepatitis B virus infection and disease progression[J]. Journal of Clinical Hepatology, 2024, 40(9): 1741-1745. doi: 10.12449/JCH240905
    [6]Shanshan XU, Lixia QIU, Yali LIU, Jing ZHANG. Risk factors and predictive models for liver cancer after sustained virologic response in hepatitis C[J]. Journal of Clinical Hepatology, 2024, 40(6): 1259-1263. doi: 10.12449/JCH240629
    [7]Yishan LIU, Lanting ZHANG, Yunyu ZHAO, Fanpu JI, Qinglei ZENG. Management of hepatitis C in children and pregnant women[J]. Journal of Clinical Hepatology, 2024, 40(4): 654-658. doi: 10.12449/JCH240402
    [8]Hongqiao ZHENG, Ailing WANG. Advances and challenges in eliminating mother-to-child transmission of hepatitis B virus worldwide[J]. Journal of Clinical Hepatology, 2024, 40(11): 2152-2157. doi: 10.12449/JCH241104
    [9]Xiaoyan WANG, Liaoyun ZHANG. Effect of treatment with direct-acting antiviral agents on the prognosis of extrahepatic diseases in patients with hepatitis C[J]. Journal of Clinical Hepatology, 2024, 40(2): 369-373. doi: 10.12449/JCH240224
    [10]Jinni HUANG, Jianning JIANG, Dandan LIANG, Shiyu LONG, Guozhen DONG, Man SU, Jijiao LI, Chunling TENG, Ping ZHANG, Minghua SU. Epidemiological features and antiviral response of genotype 6 chronic hepatitis C[J]. Journal of Clinical Hepatology, 2022, 38(4): 793-797. doi: 10.3969/j.issn.1001-5256.2022.04.011
    [11]Xinxin CHEN, Haiping ZHANG, Chunyang HUANG, Jianrong SU, Huiping YAN. Occult HBV infection in autoimmune hepatitis and its influence on disease progression[J]. Journal of Clinical Hepatology, 2022, 38(12): 2738-2743. doi: 10.3969/j.issn.1001-5256.2022.12.011
    [12]Chaomei QIN, Yongming LIU, Heling SU. Association of hepatitis B and hepatitis C with type 2 diabetes mellitus[J]. Journal of Clinical Hepatology, 2021, 37(4): 921-924. doi: 10.3969/j.issn.1001-5256.2021.04.042
    [13]Wang Qian, Bao ChunMei, He WeiPing, Cui EnBo, Zhang WenJin, Fan ZhenPing, Qu Fen. Clinical analysis of bloodstream infections caused by Escherichia coli in elderly patients with hepatobiliary disease[J]. Journal of Clinical Hepatology, 2015, 31(5): 762-765. doi: 10.3969/j.issn.1001-5256.2015.05.031
    [14]Luo ShengQiang, Wang Bin. Treatment of hepatitis: a summary of APASL Annual Meeting 2014[J]. Journal of Clinical Hepatology, 2014, 30(5): 478-480. doi: DOI: 10.3969/j.issn.1001-5256.2014.05.026
    [15]Huang YanWu, Han FengJuan. Epidemiological features and disease spectrum of hepatitis C in Qinghai Province, China: analysis of 110 cases[J]. Journal of Clinical Hepatology, 2014, 30(6): 505-507. doi: 10.3969/j.issn.1001-5256.2014.06.007
    [16]Zhu FeiYan. Clinical analysis of 119 cases of cirrhosis with infection.[J]. Journal of Clinical Hepatology, 2004, 20(2): 103-104.
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 27.9 %FULLTEXT: 27.9 %META: 53.8 %META: 53.8 %PDF: 18.2 %PDF: 18.2 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 6.9 %其他: 6.9 %其他: 0.9 %其他: 0.9 %Arlington: 0.1 %Arlington: 0.1 %China: 0.1 %China: 0.1 %Hanoi: 0.1 %Hanoi: 0.1 %Matale: 0.9 %Matale: 0.9 %Taichung: 0.1 %Taichung: 0.1 %Tiruchi: 0.1 %Tiruchi: 0.1 %三明: 0.1 %三明: 0.1 %上海: 5.7 %上海: 5.7 %东京: 0.1 %东京: 0.1 %东莞: 0.7 %东莞: 0.7 %东营: 0.1 %东营: 0.1 %临沂: 0.1 %临沂: 0.1 %乌鲁木齐: 0.1 %乌鲁木齐: 0.1 %亚特兰大: 0.1 %亚特兰大: 0.1 %伊利诺伊州: 0.1 %伊利诺伊州: 0.1 %伦敦: 0.1 %伦敦: 0.1 %佛山: 0.3 %佛山: 0.3 %保定: 0.1 %保定: 0.1 %信阳: 0.1 %信阳: 0.1 %兰州: 0.4 %兰州: 0.4 %北京: 4.1 %北京: 4.1 %华盛顿州: 0.1 %华盛顿州: 0.1 %南京: 1.0 %南京: 1.0 %南宁: 0.6 %南宁: 0.6 %南昌: 0.3 %南昌: 0.3 %卡纳塔克: 0.2 %卡纳塔克: 0.2 %厦门: 0.3 %厦门: 0.3 %合肥: 0.2 %合肥: 0.2 %咸阳: 0.2 %咸阳: 0.2 %哥伦布: 0.1 %哥伦布: 0.1 %唐山: 0.5 %唐山: 0.5 %喀什: 0.1 %喀什: 0.1 %大连: 0.3 %大连: 0.3 %天水围: 0.3 %天水围: 0.3 %天津: 0.7 %天津: 0.7 %太原: 0.6 %太原: 0.6 %奥马哈: 0.1 %奥马哈: 0.1 %娄底: 0.1 %娄底: 0.1 %孝感: 0.1 %孝感: 0.1 %孟买: 0.1 %孟买: 0.1 %宁波: 0.1 %宁波: 0.1 %安卡拉: 0.1 %安卡拉: 0.1 %安康: 0.1 %安康: 0.1 %定西: 0.1 %定西: 0.1 %宣城: 0.7 %宣城: 0.7 %常州: 0.1 %常州: 0.1 %常德: 0.1 %常德: 0.1 %广安: 0.2 %广安: 0.2 %广州: 1.6 %广州: 1.6 %廊坊: 0.1 %廊坊: 0.1 %张家口: 1.3 %张家口: 1.3 %彰化: 0.1 %彰化: 0.1 %徐州: 0.1 %徐州: 0.1 %德宏: 0.2 %德宏: 0.2 %德罕: 0.1 %德罕: 0.1 %成都: 1.0 %成都: 1.0 %扬州: 0.1 %扬州: 0.1 %抚顺: 0.1 %抚顺: 0.1 %攀枝花: 0.4 %攀枝花: 0.4 %无锡: 0.1 %无锡: 0.1 %昆明: 2.3 %昆明: 2.3 %晋城: 0.1 %晋城: 0.1 %曲靖: 0.1 %曲靖: 0.1 %朝阳: 0.3 %朝阳: 0.3 %杭州: 1.5 %杭州: 1.5 %柳州: 0.1 %柳州: 0.1 %株洲: 0.1 %株洲: 0.1 %桂林: 0.2 %桂林: 0.2 %梅州: 0.2 %梅州: 0.2 %梧州: 0.2 %梧州: 0.2 %榆林: 0.3 %榆林: 0.3 %武汉: 3.6 %武汉: 3.6 %汕头: 0.3 %汕头: 0.3 %沈阳: 0.6 %沈阳: 0.6 %沧州: 0.1 %沧州: 0.1 %泰安: 0.1 %泰安: 0.1 %泸州: 0.1 %泸州: 0.1 %洛阳: 0.4 %洛阳: 0.4 %济南: 0.7 %济南: 0.7 %济宁: 0.1 %济宁: 0.1 %海口: 0.1 %海口: 0.1 %海得拉巴: 0.5 %海得拉巴: 0.5 %淮南: 0.2 %淮南: 0.2 %深圳: 0.7 %深圳: 0.7 %温州: 0.1 %温州: 0.1 %渭南: 0.1 %渭南: 0.1 %湘潭: 0.1 %湘潭: 0.1 %湛江: 0.1 %湛江: 0.1 %漯河: 0.1 %漯河: 0.1 %特拉维夫: 0.1 %特拉维夫: 0.1 %班加罗尔: 0.1 %班加罗尔: 0.1 %甘孜: 0.1 %甘孜: 0.1 %盐城: 0.1 %盐城: 0.1 %眉山: 0.3 %眉山: 0.3 %石家庄: 0.9 %石家庄: 0.9 %福州: 0.1 %福州: 0.1 %科泽科德: 0.1 %科泽科德: 0.1 %秦皇岛: 0.1 %秦皇岛: 0.1 %绍兴: 0.1 %绍兴: 0.1 %绵阳: 0.1 %绵阳: 0.1 %自贡: 0.1 %自贡: 0.1 %舟山: 0.1 %舟山: 0.1 %芒廷维尤: 19.1 %芒廷维尤: 19.1 %芜湖: 0.1 %芜湖: 0.1 %芝加哥: 1.7 %芝加哥: 1.7 %苏州: 0.7 %苏州: 0.7 %苏黎世: 0.1 %苏黎世: 0.1 %莆田: 0.1 %莆田: 0.1 %莫斯科: 0.2 %莫斯科: 0.2 %蚌埠: 0.1 %蚌埠: 0.1 %西宁: 5.8 %西宁: 5.8 %西安: 0.9 %西安: 0.9 %西雅图: 0.1 %西雅图: 0.1 %诺沃克: 0.1 %诺沃克: 0.1 %贵港: 0.1 %贵港: 0.1 %贵阳: 0.2 %贵阳: 0.2 %赣州: 0.1 %赣州: 0.1 %赤峰: 0.1 %赤峰: 0.1 %达曼: 0.1 %达曼: 0.1 %运城: 0.5 %运城: 0.5 %遂宁: 0.1 %遂宁: 0.1 %遵义: 0.1 %遵义: 0.1 %郑州: 5.2 %郑州: 5.2 %重庆: 0.8 %重庆: 0.8 %金昌: 0.1 %金昌: 0.1 %铁岭: 0.1 %铁岭: 0.1 %银川: 0.3 %银川: 0.3 %锡林郭勒盟: 0.1 %锡林郭勒盟: 0.1 %镇江: 0.1 %镇江: 0.1 %长春: 8.4 %长春: 8.4 %长沙: 3.6 %长沙: 3.6 %长治: 0.2 %长治: 0.2 %阜阳: 0.1 %阜阳: 0.1 %青岛: 1.5 %青岛: 1.5 %马德里: 0.5 %马德里: 0.5 %马鞍山: 0.1 %马鞍山: 0.1 %鹤壁: 0.1 %鹤壁: 0.1 %其他其他ArlingtonChinaHanoiMataleTaichungTiruchi三明上海东京东莞东营临沂乌鲁木齐亚特兰大伊利诺伊州伦敦佛山保定信阳兰州北京华盛顿州南京南宁南昌卡纳塔克厦门合肥咸阳哥伦布唐山喀什大连天水围天津太原奥马哈娄底孝感孟买宁波安卡拉安康定西宣城常州常德广安广州廊坊张家口彰化徐州德宏德罕成都扬州抚顺攀枝花无锡昆明晋城曲靖朝阳杭州柳州株洲桂林梅州梧州榆林武汉汕头沈阳沧州泰安泸州洛阳济南济宁海口海得拉巴淮南深圳温州渭南湘潭湛江漯河特拉维夫班加罗尔甘孜盐城眉山石家庄福州科泽科德秦皇岛绍兴绵阳自贡舟山芒廷维尤芜湖芝加哥苏州苏黎世莆田莫斯科蚌埠西宁西安西雅图诺沃克贵港贵阳赣州赤峰达曼运城遂宁遵义郑州重庆金昌铁岭银川锡林郭勒盟镇江长春长沙长治阜阳青岛马德里马鞍山鹤壁

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (818) PDF downloads(274) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2784]YesterdayPV[4482]TodayIP[93]TodayPV[146]Online[54]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return